Modeling and Simulation Move Downstream
This article explores two commercial platforms, and touches on a new program underway in the UK.
Today, some of the most advanced computer-based models are being used for early research. However, the move to continuous processing has stimulated interest in process optimization and control. This article explores two commercial platforms, and touches on a new program underway in the UK.
Read this articlefrom Pharmaceutical Technology’s 2016 Solid Dosage Drug Development and Manufacturing eBook.
View other articles in the
2016 Solid Dosage Drug Development and Manufacturing eBook.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
